Aclaris Therapeutics ACRS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Aclaris Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's EBITDA margin?
- Aclaris Therapeutics (ACRS) reported EBITDA margin of -956.8% in Q1 2026.
- How has Aclaris Therapeutics's EBITDA margin changed year-over-year?
- Aclaris Therapeutics's EBITDA margin decreased by 21.2% year-over-year, from -789.7% to -956.8%.
- What is the long-term trend for Aclaris Therapeutics's EBITDA margin?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's EBITDA margin has grown at a -7.3% compound annual growth rate (CAGR), from -1,313.4% to -970.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.